Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 3 |
| List of Tables | 7 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 2 |
| Cloud Computing in Pharmaceutical Research and Development Key Technological Concepts | 10 | 5 |
| Core Technologies | 10 | 1 |
| Virtualization | 10 | 1 |
| Multi-tenancy | 10 | 1 |
| Web Services | 10 | 1 |
| Cloud Computing Service Models | 11 | 1 |
| Infrastructure as a Service (IaaS) | 11 | 1 |
| Platform as a Service (PaaS) | 11 | 1 |
| Software as a Service (SaaS) | 12 | 1 |
| Cloud Computing Deployment Models | 13 | 1 |
| Stakeholders | 14 | 1 |
| End-users/Consumers | 14 | 1 |
| Providers | 14 | 1 |
| Regulators | 14 | 1 |
| Enablers | 14 | 1 |
| Cloud Computing in Pharmaceutical Research and Development Competitive Landscape | 15 | 7 |
| Established Players | 15 | 1 |
| International Business Machines Corporation (IBM) | 15 | 1 |
| Google | 16 | 1 |
| Microsoft | 17 | 1 |
| Technology Providers | 18 | 1 |
| Apache | 18 | 1 |
| EMC | 19 | 1 |
| Innovative Companies | 20 | 1 |
| Amazon.com | 20 | 1 |
| Salesforce.com | 21 | 1 |
| Cloud Computing in Pharmaceutical Research and Development Technology Assessment | 22 | 4 |
| Benefits of Clouds | 23 | 1 |
| Cost Savings | 23 | 1 |
| Immediate Access to Resources | 23 | 1 |
| Lower Barriers to Innovation | 23 | 1 |
| Scalability of Services | 23 | 1 |
| New Classes of Applications and Services | 24 | 1 |
| Restraints to the Cloud | 24 | 1 |
| Security | 24 | 1 |
| Privacy and Data Location | 24 | 1 |
| Dependency on the Internet | 24 | 1 |
| System Availability and Level of Service | 24 | 1 |
| Migration of Current Applications | 25 | 1 |
| Cloud Computing in Pharmaceutical Research and Development Applications | 26 | 11 |
| Biomedical Cloud | 26 | 1 |
| Adequate Security Measures | 27 | 1 |
| Communication with Private Clouds | 27 | 1 |
| On-demand Scalability | 28 | 1 |
| Data Transfer | 28 | 1 |
| Interaction with Other Clouds | 28 | 1 |
| Next-Generation Sequencing | 28 | 1 |
| Case Study Adoption of Cloud Computing by Merck (the US) | 29 | 1 |
| Bioinformatics and Genomics | 30 | 2 |
| In Silico Research through Cloud Computing | 32 | 1 |
| The Data Layer | 32 | 1 |
| The System Layer | 33 | 1 |
| The Service Layer | 34 | 2 |
| Information Dissemination | 36 | 1 |
| Cloud Computing for Management of Clinical Trials | 36 | 1 |
| Cloud Computing in Pharmaceutical Research and Development Appendix | 37 | 3 |
| Market Definitions | 37 | 1 |
| Abbreviations | 37 | 1 |
| Bibliography | 37 | 1 |
| Research Methodology | 38 | 2 |
| Coverage | 38 | 1 |
| Secondary Research | 38 | 1 |
| Primary Research | 39 | 1 |
| Expert Panel Validation | 39 | 1 |
| Contact Us | 39 | 1 |
| Disclaimer | 39 | 1 |